Becotatug vedotin plus pucotenlimab as first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.Lu Liu, Xiaoyuan Wei, Tan Chenfeng et al.|Journal of Clinical Oncology|2026Cited by 0